Federal Supply Schedule 36F79723D0016

The U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a 5-year, $28.85 million Federal Supply Schedule (FSS) contract to Novocure Inc., a foreign-owned, for-profit manufacturer of medical devices. The contract, ID 36F79723D0016, provides a streamlined procurement vehicle for the VA to obtain Novocure's Optune line of Tumor Treating Fields (TTFields) therapy devices, transducer arrays, rental equipment, and associated support services. The primary purpose is to enable VA medical centers nationwide to offer Novocure's non-invasive cancer treatment option to veteran patients diagnosed with glioblastoma, mesothelioma, and other solid tumor cancers, supporting the VA's mission of expanding access to innovative therapies. The contract does not utilize any set-aside designations. Under this FSS contract, the VA has issued numerous delivery orders to Novocure, valued from $16,582.91 to $99,497.46, for the provision of Optune Plus transducers, device rentals, and related support services to be delivered to VA facilities across the country, including in Portsmouth, New Hampshire; San Antonio, Texas; Des Moines, Iowa; and other locations.

The VA VHA is the primary funding agency for this contract, as it aims to procure Novocure's specialized cancer treatment technologies to enhance veterans' access to cutting-edge therapies. Novocure is the prime contractor on all the delivery orders issued under the FSS contract, directly delivering its proprietary Optune system to VA medical centers without the use of subcontractors. The contract's firm fixed-price structure and lack of set-aside designations likely reflect the specialized nature of Novocure's medical device offerings.